Gan & Lee Pharmaceuticals (603087.SH): It is expected that the Sitagliptin phosphate tablets will be launched for sales after the expiration of the original research product patent in the second half of the year.

Gelonghui Finance · Jul 10 11:46

On July 10th, Gelonhui reported that Gan & Lee Pharmaceuticals (603087.SH) stated on its investor platform that GZR4 is a new long-acting basal insulin analogue independently developed by Gan & Lee Pharmaceuticals, designed for once-a-week administration. In addition, the Sitagliptin Phosphate Tablets is the company's first independently developed oral hypoglycemic drug, which is expected to be launched for sale after the expiration of the original patented product in the second half of 2024.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

甘李药业(603087.SH)：磷酸西格列汀片预计将于下半年原研产品专利到期后上市销售

Gan & Lee Pharmaceuticals (603087.SH): It is expected that the Sitagliptin phosphate tablets will be launched for sales after the expiration of the original research product patent in the second half of the year.

Risk Disclaimer

Statement